$16.04
-3.0%BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
BIOA • NASDAQ
| BioAge Labs, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-80.6M | -71.1M | -63.9M | -39.7M | |
213K | 167K | 162K | 129K | |
11.7M | 7M | 3M | 2.5M | |
-1.1M | 1.3M | 16.6M | 77K | |
-11.8M | 11.2M | 6.7M | 795K | |
-81.6M | -51.5M | -37.4M | -36.2M | |
INVESTING ACTIVITIES | ||||
-719K | -366K | -166K | -103K | |
-154.7M | (0.0) | -100K | (0.0) | |
60.3M | 0.0 | 0.0 | 0.0 | |
-95.2M | -366K | -266K | -103K | |
FINANCING ACTIVITIES | ||||
17.5M | 221.6M | 0.0 | 0.0 | |
-6M | -6M | 35M | 2.5M | |
0.0 | -4.4M | -59K | -1K | |
11.5M | 381.2M | 34.9M | 2.5M | |
CASH FLOW SUMMARY | ||||
-87K | 81K | 0.0 | 246K | |
-165.5M | 329.4M | -2.7M | -33.5M | |
354.3M | 25M | 27.6M | 61.2M | |
188.9M | 354.3M | 25M | 27.6M | |
-82.3M | -51.9M | -37.5M | -36.3M |
BIOA - Filing history and reports
No SEC filings available for BIOA
Continue your BIOA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.